The Quad Investors Network Launches with Advisory Board, Expert Groups
20.5.2023 17:43:00 EEST | Business Wire | Press release
The Quad Investors Network formally launched today in parallel with the Quad Leaders meeting in Hiroshima, Japan. The Network is an independent forum of public, private, and philanthropic stakeholders from the four Quad nations, created to foster cooperation, collaboration, and co-investment into critical technologies and supply chain resilience to develop innovative solutions to the greatest economic and security challenges in the Indo-Pacific region. Membership in the network is by invitation only.
Governments participating in the security dialogue, a strategic endeavor between Australia, India, Japan, and the United States, also jointly welcomed the formation of the board and the network’s continued efforts to expand capital and partnership opportunities in critical and emerging technologies across the Quad.
“Critical and emerging technologies will profoundly shape our future. By seeking to accelerate the development and manufacturing of these technologies, from semiconductors to quantum to clean energy, the Quad Investors Network demonstrates the tremendous potential of the Quad nations to mobilize world-class talent and investment to foster a more prosperous, resilient, and innovative Indo-Pacific,” said Jake Sullivan, U.S. National Security Advisor.
As part of the launch, the Quad Investors Network announced the formation of an Advisory Board, composed of world-class business, investment, and thought leaders from the four Quad nations. The Advisory Board includes former Telstra CEO Andy Penn AO; former Australian Ambassador to the United States Arthur Sinodinos AO; Founder and CEO of Breyer Capital Jim Breyer; former Bell Labs President Jeong Kim; Chairman Emeritus of JSR Corporation Koshiba Mitsunobu; and Japan Business Federation Managing Director Hara Ichiro.
“The Quad Investors Network serves as an important, exciting forum for executives, investors, and technologists to collaborate and generate greater co-investment in critical and emerging technologies. These technologies will only grow in importance in the future, and I am honored to be a member of the network’s Advisory Board,” said former Telstra CEO Andy Penn.
The Quad Investors Network also established five expert working groups focused on artificial intelligence, semiconductors, clean energy and critical minerals, mobile networks, and quantum information sciences.
Entrepreneur and investor Karl Mehta will serve as the inaugural Chairman of the Quad Investors Network. Mehta is a serial entrepreneur, author, investor, engineer, and civil servant with more than 30 years of experience in founding, building, and funding technology companies in the U.S. and international markets.
“I am honored to lead, and be a part, of such an august group of individuals and organizations which have come together to work on some of the most pressing critical technology issues facing the Quad,” said Mehta. “I look forward to making further progress and contributing to the economic and national security of the four Quad nations through our efforts.”
Full List of the Quad Investors Network Advisory Board:
- Thomas Bell, CEO of Leidos
- Jim Breyer, Founder and CEO of Breyer Capital
- Kris Gopalakrishnan, Chairman of Axilor Ventures
- Hara Ichiro, Managing Director of Japan Business Federation
- Hon. Joe Hockey, Founding Partner and President of Bondi Partners
- Ashok Jacob, Executive Chairman and Portfolio Manager for Ellerston Capital
- Lydia Jett, Managing Partner at Softbank Investment Advisers
- Jeong Kim, Chairman of Kiswe Mobile Inc.
- Koshiba Mitsunobu, Chairman Emeritus of JSR Corporation
- Arun Kumar, Managing Partner of Celesta Capital
- Paul Kwan, General Partner at General Catalyst
- Nakahama Fumitaka, Managing Corporate Executive and Group Head of Global Corporate and Investment Banking Business at MUFG
- Jeff Nuechterlein, Managing Partner of Nue Capital LLC
- Andy Penn AO, Former CEO of Telstra
- Bec Shrimpton, Defence Strategy and National Security Director at the Australian Strategic Policy Institute
- Hon. Arthur Sinodinos AO, Former Australian Ambassador to the United States
- Hon. Sugiyama Shinsuke, Former Japanese Ambassador to the United States
- Yanase Tadao, Senior Executive Vice President at Nippon Telegraph and Telephone Corporation
- Ankur Verma, Senior Vice President at Tata Sons
About The Quad Investors Network: The Quad Investors Network (“The Network”) was formed to develop innovative solutions to the greatest economic and security challenges facing the Quad nations in the Indo-Pacific region through joint research, co-investments, and strategic partnerships. The network will be an independent, membership forum composed of leading industry, government, capital market, and academic organizations from the Quad nations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230520005025/en/
Contact information
Alex El-Fakir
201-328-2930
info@quadinvestorsnetwork.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
